biopharmaceutical – media

Important Registration Regulations for Exporting Health Care Products to Vietnam

With the continuous improvement of living standards in recent years, the Vietnamese people’s demands for healthcare products have increased significantly. Compared with others, Vietnamese acceptance of healthcare products is later than most other countries.
- Source: Ddu
- 4,935
- March 31, 2022
biopharmaceutical Policies Vietnam
AbbVie Investors Need not Abandon Ship yet

After watching Scott Gottlieb, M.D. of the FDA comments regarding the rebate rule changes and a warning tweet on biosimilars, AbbVie investors are bailing out. But the industry watchers claim that they don’t need to be.
- Source: FiercePharma
- 1,086
- July 24, 2018
AbbVie biopharmaceutical FDA Market Views
Emergent BioSolutions to Invest $50M for Expansion

Emergent BioSolutions, Gaithersburg, Maryland-based Biopharmaceutical Company announced that it will invest $50 million for the next three years to expand the manufacturing capacity for its Camden fill-finish in Baltimore facility. By the time the project has been completed in three years, it is expected to add up 60 jobs.
- Source: FiercePharma
- 781
- June 11, 2018
biopharmaceutical Company Insight
Athenex Manufacturing $200 Million Plant at Dunkirk, NY, USA

The global biopharmaceutical company revealed its proposal for the new facility two years back when it signed its agreement with German-based construction engineering company M+W, the plant is expected to be 320,000 square feet. The factory will employee about 900 people, which is scheduled to operate in full- fledge by the first half of 2020.
- Source: Ddu
- 751
- May 30, 2018
biopharmaceutical Company Insight
Trump calls for FDA price check with drug prices in ads

A particular proposal regarding displaying drug prices in TV ads flummoxed pharma marketers and ad agencies following the unveiling of the drug-pricing agenda by President Trump. Marketers have been hounded with the whys and hows of the proposal even as the administration remains firm on its implementation.
- Source: Ddu
- 811
- May 17, 2018
biopharmaceutical FDA pharma Policies
Huge biologics plant planned to be built by Sinobioway Biomedicine

Plans are afoot at Shandong Sinobioway Biomedicine Co. in China to construct a huge biologics plant as the country moves towards cell-based drugs.
- Source: drugdu
- 854
- May 15, 2018
biopharmaceutical China Market Views
Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X–Linked Hypophosphatemia (XLH)

First Approved Therapy for XLH in the U.S.; Only Treatment that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease
- Source: globenewswire
- 949
- April 19, 2018
biopharmaceutical FDA New Approvals rare and ultra-rare diseases
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to SAGE-217 for the treatment of major depressive disorder (MDD). This is the second Breakthrough Therapy designation granted to Sage since 2016.
- Source: finance.yahoo
- 746
- February 12, 2018
biopharmaceutical FDA major depressive disorder New Approvals
Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement ("the Agreement") with Eisai Co., Ltd. ("Eisai"), a global pharmaceutical company with a focus on serving patients with unmet medical needs.
- Source: Prnewswire
- 768
- January 22, 2018
biopharmaceutical EP4 antagonist Market Views
AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

AbbVie, a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. , announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being investigated for the management of endometriosis with associated pain.
- Source: news.abbvie
- 734
- November 2, 2017
antagonist biopharmaceutical GnRH New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.